Your browser doesn't support javascript.
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.
Tian, Jianbo; Yuan, Xianglin; Xiao, Jun; Zhong, Qiang; Yang, Chunguang; Liu, Bo; Cai, Yimin; Lu, Zequn; Wang, Jing; Wang, Yanan; Liu, Shuanglin; Cheng, Biao; Wang, Jin; Zhang, Ming; Wang, Lu; Niu, Siyuan; Yao, Zhi; Deng, Xiongbo; Zhou, Fan; Wei, Wei; Li, Qinglin; Chen, Xin; Chen, Wenqiong; Yang, Qin; Wu, Shiji; Fan, Jiquan; Shu, Bo; Hu, Zhiquan; Wang, Shaogang; Yang, Xiang-Ping; Liu, Wenhua; Miao, Xiaoping; Wang, Zhihua.
  • Tian J; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yuan X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Xiao J; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhong Q; Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yang C; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu B; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cai Y; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Lu Z; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang J; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang Y; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu S; Department of Urology, Wuhan First Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cheng B; Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang J; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang M; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang L; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Niu S; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yao Z; Department of Respirology and Tuberculosis Specialty, Wuhan Pulmonary Hospital, Wuhan, China.
  • Deng X; Department of Radiology, Wuhan Jinyintan Hospital, Wuhan, China.
  • Zhou F; Department of Urology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wei W; Department of Urology, The Fifth Hospital of Wuhan, Wuhan, China.
  • Li Q; Department of Respiratory Medicine, Wuhan Hankou Hospital, Wuhan, China.
  • Chen X; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chen W; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yang Q; Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wu S; Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Fan J; Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Shu B; Department of Urology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hu Z; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang S; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yang XP; Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu W; Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Miao X; Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang Z; Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: zhwang_hust@hotmail.com.
Lancet Oncol ; 21(7): 893-903, 2020 07.
Article in English | MEDLINE | ID: covidwho-436717
Semantic information from SemMedBD (by NLM)
1. risk factors PROCESS_OF Patients
Subject
risk factors
Predicate
PROCESS_OF
Object
Patients
2. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
3. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
4. Malignant Neoplasms NEG_PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
NEG_PROCESS_OF
Object
Patients
5. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
6. follow-up TREATS Patients
Subject
follow-up
Predicate
TREATS
Object
Patients
7. Lymphopenia PROCESS_OF Patients
Subject
Lymphopenia
Predicate
PROCESS_OF
Object
Patients
8. Disease Progression PROCESS_OF Patients
Subject
Disease Progression
Predicate
PROCESS_OF
Object
Patients
9. Malignant Neoplasms COEXISTS_WITH COVID-19
Subject
Malignant Neoplasms
Predicate
COEXISTS_WITH
Object
COVID-19
10. risk factors PROCESS_OF Patients
Subject
risk factors
Predicate
PROCESS_OF
Object
Patients
11. Malignant Neoplasms PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
PROCESS_OF
Object
Patients
12. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
13. Malignant Neoplasms NEG_PROCESS_OF Patients
Subject
Malignant Neoplasms
Predicate
NEG_PROCESS_OF
Object
Patients
14. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
15. follow-up TREATS Patients
Subject
follow-up
Predicate
TREATS
Object
Patients
16. Lymphopenia PROCESS_OF Patients
Subject
Lymphopenia
Predicate
PROCESS_OF
Object
Patients
17. Disease Progression PROCESS_OF Patients
Subject
Disease Progression
Predicate
PROCESS_OF
Object
Patients
18. Malignant Neoplasms COEXISTS_WITH COVID-19
Subject
Malignant Neoplasms
Predicate
COEXISTS_WITH
Object
COVID-19
ABSTRACT

BACKGROUND:

COVID-19 has spread globally. Epidemiological susceptibility to COVID-19 has been reported in patients with cancer. We aimed to systematically characterise clinical features and determine risk factors of COVID-19 disease severity for patients with cancer and COVID-19.

METHODS:

In this multicentre, retrospective, cohort study, we included all adult patients (aged ≥18 years) with any type of malignant solid tumours and haematological malignancy who were admitted to nine hospitals in Wuhan, China, with laboratory-confirmed COVID-19 between Jan 13 and March 18, 2020. Enrolled patients were statistically matched (21) with patients admitted with COVID-19 who did not have cancer with propensity score on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, illness severity, and clinical interventions were compared between patients with COVID-19 with or without cancer as well as between patients with cancer with non-severe or severe COVID-19. COVID-19 disease severity was defined on admission on the basis of the WHO guidelines. Univariable and multivariable logistic regression, adjusted for age, sex, comorbidities, cancer type, tumour stage, and antitumour treatments, were used to explore risk factors associated with COVID-19 disease severity. This study was registered in the Chinese Clinical Trial Register, ChiCTR2000030807.

FINDINGS:

Between Jan 13 and March 18, 2020, 13 077 patients with COVID-19 were admitted to the nine hospitals in Wuhan and 232 patients with cancer and 519 statistically matched patients without cancer were enrolled. Median follow-up was 29 days (IQR 22-38) in patients with cancer and 27 days (20-35) in patients without cancer. Patients with cancer were more likely to have severe COVID-19 than patients without cancer (148 [64%] of 232 vs 166 [32%] of 519; odds ratio [OR] 3·61 [95% CI 2·59-5·04]; p<0·0001). Risk factors previously reported in patients without cancer, such as older age; elevated interleukin 6, procalcitonin, and D-dimer; and reduced lymphocytes were validated in patients with cancer. We also identified advanced tumour stage (OR 2·60, 95% CI 1·05-6·43; p=0·039), elevated tumour necrosis factor α (1·22, 1·01-1·47; p=0·037), elevated N-terminal pro-B-type natriuretic peptide (1·65, 1·03-2·78; p=0·032), reduced CD4+ T cells (0·84, 0·71-0·98; p=0·031), and reduced albumin-globulin ratio (0·12, 0·02-0·77; p=0·024) as risk factors of COVID-19 severity in patients with cancer.

INTERPRETATION:

Patients with cancer and COVID-19 were more likely to deteriorate into severe illness than those without cancer. The risk factors identified here could be helpful for early clinical surveillance of disease progression in patients with cancer who present with COVID-19.

FUNDING:

China National Natural Science Foundation.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Neoplasms Type of study: Controlled clinical trial / Etiology study / Clinical Practice Guide / Observational study / Prognostic study / Randomized controlled trials / Risk factors Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Lancet Oncol Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: S1470-2045(20)30309-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Neoplasms Type of study: Controlled clinical trial / Etiology study / Clinical Practice Guide / Observational study / Prognostic study / Randomized controlled trials / Risk factors Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Lancet Oncol Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: S1470-2045(20)30309-0